Antacids Market Growth Accelerating with Consumption of High Cholesterol Food and Rise in the Prevalence of Heartburn and GERD | Future Market Insights, Inc.

The United States holds around 28.1% share of the global antacids market and is projected for continued profitable growth. The prevalence of gastrointestinal issues is on the rise, and antacid products are becoming widely known among consumers in the United States.


NEWARK, Del, Nov. 14, 2023 (GLOBE NEWSWIRE) -- As per Future Market Insights latest industry analysis, the valuation for the global antacids market The market to be worth US$ 6,971.2 million by the end of 2023 and further expand at a CAGR of 4.9% to reach a valuation of US$ 11,194.8 million by 2033.

Antacids are commonly used due to their affordability and help to reduce inflammation, swelling, and pain. Likewise, changing lifestyles such as unstable eating patterns, sedentary lifestyles, and sleep patterns are favorably influencing market growth. The development of safe and effective raft-forming antacids that have a longer duration of action and higher efficacy is one of the many product advancements that are boosting the market's expansion.

Pharmaceutical manufacturers are concentrating on developing new drug discoveries, formulation of tablets, and different drug dosages. Furthermore, antacids are widely acceptable by several patients as they can be used as an effective medication for clinical conditions. As a result, the antacids market will drive throughout the forecast period.

Request Sample Report: Empower Your Industry Understanding with Invaluable Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18182

Key Takeaways from the Market Study

  • Proton pump inhibitors are the leading segment of antacids and hold around 25.3% market value share in 2022, proton pump inhibitors reduce gastroesophageal reflux disorder and also treat stomach ulcers or duodenal. PPI is generally available in the form of tablets or capsules.
  • The tablet segment is set to lead in terms of indication of antacids with a projected market value share of around 25.5% by 2022; generally, tablets of antacids are used to take in conditions like acidity and heartburn.        
  • By route of administration, oral is leading in the global antacids market and is expected to continue to do so with a projected CAGR of 4.4% during the forecasted years, with a market share of 64.4% in the year 2022.
  • Gastroesophageal reflux disease holds the highest share in the antacids market, with a market value share of 49.2% and a CAGR of 4.7% during the projected forecasted period. Being overeating, overweight, eating chocolate and spicy foods as well as consuming caffeine and alcohol are some lifestyle choices that may contribute to GERD.
  • Retail pharmacies as a distribution channel are leading in the global antacids market and are expected to continue to do so with a projected CAGR rate of 4.4% during the forecasted years, with a market share of 44.0% in the year 2022.
  • North America is considered the leading region with a value share of 31.2% in 2022, owing to the high prevalence of diseases like GERD and heartburn.

Rising focus toward developing new antacids substance and new drugs launches, the antacids market is expected to witness an advancement over the forecasted years,” Says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights into the antacids market in its latest study. It presents a historical demand assessment of 2018 to 2022 and projections for 2023 to 2033. The global market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader

The research study is based on the drug class (proton pump inhibitors, h2 antagonists, acid neutralizers, pro-motility agents, anti-h.pyrolic drugs, prostaglandin analogous, others), by dosage form (tablet, capsules, powder, liquid, others), by route of administration (oral, injectable), by indication (gastroesophageal reflux disease, heartburn, ulcer, others), by distribution channel (retail pharmacies, hospital pharmacies, online pharmacies) across seven key regions of the world.

Scope Of Report:

AttributeDetails
Forecast Period2018 to 2022
Historical Data Available for2023 to 2033
Market AnalysisUS$ million for Value
Key Regions CoveredNorth America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries CoveredUnited States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa
Key Market Segments CoveredDrug Class, Dosage Form, Route of Administration, Indication, Distribution Channel and Region
Key Companies Profiled
  • Johnson and Johnson
  • Sanofi S.A.
  • Bayer AG
  • Sun Pharmaceuticals Ltd
  • Zydus Lifesciences
  • Abbott Laboratories
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Takeda Pharmaceutical Company Limited.
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • Novartis AG
  • Lupin
  • Cipla Inc
  • Aurobindo Pharma
  • Fresenius Kabi AG
  • Alkem Labs.

Market Competition

The market for antacids is fragmented, and there exist several local, upcoming, as well as established players within the market. Key players have initiated marketing initiatives to educate the elderly population about the benefits of antacids while also attempting to improve the drugs with different specifications.

  • On 22 February 2022, Alkem Labs, Omee antacid brand, started a new advertising campaign called ‘Sabko Pata Hai, India Ka Favorite Antacid hai Omee.’ The campaign's objectives are to make India laugh and to spread awareness that Omee is the treatment for all acidity issues.
  • On 20 October 2020, Dr. Reddy's Laboratories Ltd. announced the launching of the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg. These tablets are used for heartburn prevention and relief from acid reducers.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.futuremarketinsights.com/checkout/18182

Key Market Segments Covered in Antacids Industry Research

By Drug Class:

  • Proton Pump Inhibitors
  • H2 Antagonist
  • Acid Neutralizers
  • Pro-Motility Agents
  • Anti-H.Pyrolic Drugs
  • Prostaglandin Analogous
  • Others

By Dosage form:

  • Tablet
  • Capsules
  • Powder
  • Liquid
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Indication:

  • Gastroesophageal Reflux Disease
  • Heartburn
  • Peptic Ulcer
  • Others

By Distribution channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI's Extensive Coverage in Healthcare Domain:

Liver Transplantation Market Size: The current market value for this market is likely to reach US$ 1,409.8 million. The market is expected to be worth around US$ 2,653.4 million by 2033.

Neurostimulation Market Overview: The market is expected to grow at a promising CAGR of 9.5% through 2033, with a forecast valuation of US$ 15,417.4 million by 2033. 

Microfluidics Market Review: This market is set for significant expansion, with an anticipated valuation of US$ 7,711.9 million by 2023. The market displays a considerable trend, featuring a noteworthy CAGR of 11.9%, expected to endure until 2033.

Surgical Stapling Device Market Analysis: The market is projected to be valued at US$ 3,977.40 million in 2023. The market research report anticipates a growth of US$ 5,930.60 million by 2033.

Liquid Biopsy Market Outlook: The global Market share is estimated to clock a revenue of US$ 1,538.3 million in 2023. Our healthcare domain experts opine that the market providers can expect a robust CAGR of 21.7% through 2033

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube